Journals / Anatolian Current Medical Journal / 2019 / Cilt: 1 - Sayı: 1

Linezolide, a member of oxazolidinones group antibiotics which is used in resistant Gram positive infections

Dirençli Gram pozitif bakteriyel enfeksiyonlarinda kullanilan oksazolidinon grubu bir antibiyotik: linezolid

Pages
14–17
Publication Date
2019-01-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antimicrobial spectrum, clinical use and adverse effects of linezolid is summarized in this review.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Management of infections due to resistant gram positive microorganisms such as metisilin resistant Staphylococcus aureus, vancomycin resistant enterococcus, penicillin resistant pneumococcus is a new challenge for physicians by increasingly rates of antibiotic resistance.
📊
Key Findings & Data:The mechanism of action is involving inhibition of the initiation of bacterial protein synthesis coupling ribosomal 50 S unit.
💡
Conclusion & Impact:Antimicrobial spectrum, clinical use and adverse effects of linezolid is summarized in this review.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Linezolid · etki spektrumu · endikasyon

Abstract

Management of infections due to resistant gram positive microorganisms such as metisilin resistant Staphylococcus aureus, vancomycin resistant enterococcus, penicillin resistant pneumococcus is a new challenge for physicians by increasingly rates of antibiotic resistance. Linezolid which is an agent used for the treatment of these resistant gram positive bacterial infections is a member of oxazolidinones. The mechanism of action is involving inhibition of the initiation of bacterial protein synthesis coupling ribosomal 50 S unit. It is bacteriostatic against most bacteria. The most important adverse effect is hematologic toxicity (thrombocytopenia and anemia) especially in longer usage more than four weeks. Antimicrobial spectrum, clinical use and adverse effects of linezolid is summarized in this review.

Özet

Günümüzde metisiline dirençli Staphylococcus aureus ve vankomisine dirençli enterokoklar,penisiline dirençli pnömokoklar gibi dirençli gram pozitif bakteriyel enfeksiyonların tedavisi önemli bir sorundur. Dirençli gram pozitif bakteriyel enfeksiyonların tedavisinde kullanılan linezolid oksazolidinon grubunda bir antibiyotiktir. Etki mekanizması ribozom 50 S ünitesine bağlanarak protein sentezini inisiasyon fazında inhibe eder. Bakteriostatik etkilidir. En önemli yan etkisi 4 haftadan uzun süre ile kullanımda hematolojik yan etkilere (trombositopeni ve anemi) neden olmasıdır. Bu yazıda linezolidin etki spektrumu, endikasyonları ve yan etkileri özetlenmiştir.

🔖

Cite This Article

KARAKÖK, T., KINIKLI, S., CESUR, S. (2019). Linezolide, a member of oxazolidinones group antibiotics which is used in resistant Gram positive infections. Anatolian Current Medical Journal, Cilt: 1 - Sayı: 1, 14–17. https://ajindex.com/articles/733923

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42
  2. Diekema D, and Jones R. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-81
  3. Ager A, and Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 2012; 5: 87-10
  4. Larruskain J, Idigoras P, Marimón JM, et al. Susceptibility of 186. Antimicrob Agents Chemother 2011; 55: 2995-8
  5. Ashtekar DR, Costa-Periera R, Shrinivasan T, et al. Oxazolidinones, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against. Diagn Microbiol Infect Dis 1991; 14: 465-71
  6. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802
  7. Willke A, Doganay M, Söyletir G, Nobel Kitabevi, İstanbul, 2008; cilt 1: 337-41
  8. Meka VG, and Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39: 1010-5
  9. Stalker DJ, and Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40
  10. Zyvox® (linezolid) [package insert]. New York: Pharmacia and Upjohn Company, 2012
  11. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6
  12. Dennis, L. Stevens, Lempiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90
  13. Yue J, Dong BR, Yang M, Chen X, Wu T, Liu G. Linezolid versus vancomycin for skin and soft tissue infections. status and date: Edited (no change to conclusions), published in 2016: Iss 1
  14. Wunderink RG, Cammarat SK, Oliphant T, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Therapeutics 2003; 25: 980-92.15. Rubinstein E, Cammarat SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12
  15. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: 2-Volume Set, 8e, 2015
  16. Lee M, Lee J, Carrol MW, et al. Linezolid for treatment of chronic extensively drug